ADVANCED SOLID TUMORS CANCER
Clinical trials for ADVANCED SOLID TUMORS CANCER explained in plain language.
Never miss a new study
Get alerted when new ADVANCED SOLID TUMORS CANCER trials appear
Sign up with your email to follow new studies for ADVANCED SOLID TUMORS CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can your own immune cells beat advanced cancer?
⭐️ CURE ⭐️ Not yet recruitingThis trial tests a personalized therapy called GT201, made from a patient's own tumor-infiltrating lymphocytes (TILs). The goal is to see if these immune cells, grown in the lab and infused back into the patient, can shrink or eliminate advanced solid tumors. The study includes a…
Matched conditions: ADVANCED SOLID TUMORS CANCER
Phase: PHASE1, PHASE2 • Sponsor: Gritbio Medicine, Inc. • Aim: ⭐️ CURE ⭐️
Last updated Aug 16, 2026 00:00 UTC
-
Blood test may let cancer patients take safe breaks from immunotherapy
Disease control Not yet recruitingThis trial investigates whether a sensitive blood test (Signatera) can detect when it is safe to pause immunotherapy in people with advanced solid tumors like lung cancer, melanoma, and colorectal cancer. Participants are randomly assigned to either continuous standard immunother…
Matched conditions: ADVANCED SOLID TUMORS CANCER
Phase: NA • Sponsor: Natera, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with RAS mutations
Disease control Not yet recruitingThis study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…
Matched conditions: ADVANCED SOLID TUMORS CANCER
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New cancer drug targets HER3 in advanced tumors
Disease control Not yet recruitingThis study tests a new drug called KHN922 in people with advanced solid tumors that have not responded to standard treatments. KHN922 is an antibody-drug conjugate designed to target HER3 proteins on cancer cells and deliver two anti-cancer drugs directly to them. The trial will …
Matched conditions: ADVANCED SOLID TUMORS CANCER
Phase: PHASE1, PHASE2 • Sponsor: Chengdu Kanghong Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC